Yasmin Indications and Dosage
- acne vulgaris †
- amenorrhea †
- contraception
- dysfunctional uterine bleeding †
- endometriosis †
- hirsutism †
- polycystic ovary syndrome †
† non-FDA-approved indication
Yasmin (Drospirenone; Ethinyl Estradiol) Indications and Dosage
For routine contraception:
Oral dosage (Yasmin® monophasic formulation):
Adult and adolescent females: 1 tablet (containing 3 mg drospirenone and 30 mcg of ethinyl estradiol) PO once daily for 21 days, followed by 7 days without drug. Repeat dosage cycle begins on the eighth day after taking the last hormonally active tablet. Most monophasic fixed-combination OC cycles begin on the first Sunday after or on which bleeding has started, or alternatively, on day 1 of the menstrual cycle (1st day of menstruation) .
For the treatment of severe acne vulgaris † related to sebum overproduction in females with no contraindications to OCs, who have achieved menarche and desire contraception, and who are unresponsive to topical anti-acne medications:
Oral dosage:
Adult and adolescent females: Follow dose as for routine contraception. Improvement may not be noticeable for 2—4 months; prolonged use may be needed for acne control.
For the treatment or adjuvant treatment of amenorrhea † , dysfunctional uterine bleeding † , hirsutism † , hypermenorrhea † , or polycystic ovary syndrome † related to hypoestrogenic or hyperandrogenic conditions in females with no contraindications to OCs, who have achieved menarche and desire contraception, and who have been evaluated for causes of the condition:
Oral dosage:
Adult and adolescent females: Follow dose as for routine contraception. Treatment for 6—12 months may be required; OCs have limited utility when the underlying cause of the condition is not related to a hypoestrogenic or hyperandrogenic state.
For the treatment of endometriosis † to induce endometrial involution to a ‘resting’ phase and reduce the size and growth of endometrial tissue in females with no contraindications to OCs, who have achieved menarche and desire contraception:
Oral dosage:
Adult and adolescent females: Follow dose as for routine contraception; alternatively, the active tablets can be given continuously. Treatment for 6—9 months may be needed to induce endometrial atrophy and reduce symptoms.
Maximum Dosage Limits:
- Adults: Dependent on product used and indication for therapy.
- Elderly: Not indicated.
- Adolescents: Dependent on product used and indication for therapy.
- Children: Not indicated in prepubescent females.
Patients with hepatic impairment:
Use of drospirenone-ethinyl estradiol is contraindicated if hepatic dysfunction is present (manufacturer’s information).
Patients with renal impairment:
CrCl < 80 ml/min: Use of drospirenone-ethinyl estradiol is contraindicated in renal impairment (manufacturer’s information).
† non-FDA-approved indication
[ Last revised: 1/23/2003 12:50:00 PM ]
Related entries
Syndicate
|
